Is Retatrutide a GLP-3? The Naming Explained
By the NexXGEN Research Team · Updated October 19, 2026 · 4 min read
Key takeaways
- “GLP-3” is a market nickname. It is not an official class, and no regulator or naming body assigns it.
- Retatrutide is a triple agonist that acts at three receptors: GLP-1R, GIPR and GCGR.
- It is a synthetic, modified peptide, so it is stored and handled like other lyophilized research peptides.
- For lab work, the name on the label matters less than the batch-specific identity and purity data.
- All NexXGEN compounds are sold for in-vitro, laboratory research use only.
Short answer: no. “GLP-3” is informal shorthand, not a pharmacological class. The compound people usually mean by it is retatrutide, which acts on three receptors (GLP-1R, GIPR and GCGR) rather than on a single “GLP-3” receptor, and no such receptor exists.
This guide is for researchers who want a clean, lab-oriented answer, and a checklist for confirming what is actually in the vial. In the NexXGEN catalog this compound is listed as NXGN-3 R (GLP-3 R, retatrutide); GLP-3 R is the name printed on the vial label.
Is retatrutide a GLP-3?
Not in any formal sense. The “GLP” in these names stands for glucagon-like peptide, and the numbers people attach to it are not a standard series. There is no recognized “GLP-3” receptor, no assigned drug name, and no pharmacological class by that title. Using it as a search term is common. Using it as a technical label invites confusion.
Why does the “GLP-3” nickname exist?
It grew out of how the field is discussed. Semaglutide acts at GLP-1R and is often called a “GLP-1.” Tirzepatide adds GIPR activity and is often called a “dual agonist.” Retatrutide adds a third target, the glucagon receptor, so it was informally pictured as the next step: “GLP-3.” Sellers and forums adopted the shorthand because it is short and easy to search. It describes where the compound sits in a sequence of ideas, not what it is chemically.
Is reta a peptide?
Yes. “Reta” is a common abbreviation for retatrutide, a synthetic peptide agonist that is chemically modified, including with a lipid side chain. In the lab it is supplied as a lyophilized powder, kept cold and dry, and reconstituted in a suitable solvent before use.
How does the receptor profile compare with related research peptides?
| Compound | GLP-1R | GIPR | GCGR | Common informal label |
|---|---|---|---|---|
| Semaglutide | Yes | No | No | “GLP-1” |
| Tirzepatide | Yes | Yes | No | “GLP-2” / dual agonist |
| Retatrutide | Yes | Yes | Yes | “GLP-3” / triple agonist |
The table summarizes receptor targets only. For exact sequence and structure, rely on the compound’s documented identity and the mass-spectrometry data on its COA, not on a product label or nickname.
What should a researcher check instead of the name?
Because nicknames vary between sellers, verify the material itself:
- Compound name. Does the certificate of analysis (COA) state the chemical identity, not just “GLP-3”?
- Batch match. Does the batch or lot number on the vial match the one on the COA?
- Identity. Is molecular mass confirmed by mass spectrometry?
- Purity. Is purity reported by HPLC, with the chromatogram available?
- Source of the data. Is the testing laboratory named, and is the report dated?
- Handling. Does the supplier give storage guidance?
For a step-by-step walkthrough of identity and purity data, see how to read a peptide COA, or browse the Analytical Methods section of the Research Library.
Related research guides
- Is tirzepatide a GLP-2? Dual-agonist naming explained
- How to read a peptide COA
- GHK-Cu: peptide chemistry and stability
- Browse the full Research Library
- Research peptides catalog
Research-use note
All Nexxgen Peptides compounds are intended strictly for in-vitro research, laboratory and analytical purposes. They are not for human or animal use, are not approved by the U.S. Food and Drug Administration, and must be handled only by qualified researchers aged 21 or older. Nothing in this article is medical advice.
Frequently asked questions
Is GLP-3 an official drug class?
No. GLP-3 is not a recognized pharmacological class or an assigned drug name. It is informal shorthand, usually applied to retatrutide.
Is retatrutide the same as semaglutide or tirzepatide?
No. Semaglutide targets GLP-1R, tirzepatide targets GLP-1R and GIPR, and retatrutide targets GLP-1R, GIPR and the glucagon receptor (GCGR). They are different molecules with different sequences.
Is retatrutide a peptide?
Yes. It is a synthetic, modified peptide agonist, which is why it is handled as a lyophilized peptide in the laboratory.
Why do some labels say GLP-3 and others say retatrutide?
Sellers use different shorthand. The label alone does not confirm identity. Check the compound name, mass and purity on a batch-specific certificate of analysis.
How can I confirm what is in a vial?
Match the vial’s batch number to a COA showing identity by mass spectrometry and purity by HPLC from an independent or clearly identified laboratory.
